Poster #T45 CHANGES IN BODY MASS AND METABOLIC PROFILES OVER 12 MONTHS IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA WITH ASSURED ANTIPSYCHOTIC ADHERENCE

2014 ◽  
Vol 153 ◽  
pp. S305
Author(s):  
Bonginkosi Chiliza ◽  
Laila Asmal ◽  
Piet Oosthuizen ◽  
Yvette van Niekerk ◽  
Rajiv Erasmus ◽  
...  
2015 ◽  
Vol 30 (2) ◽  
pp. 277-283 ◽  
Author(s):  
B. Chiliza ◽  
L. Asmal ◽  
P. Oosthuizen ◽  
E. van Niekerk ◽  
R. Erasmus ◽  
...  

AbstractObjectives:To assess changes in body mass and metabolic profiles in patients with first-episode schizophrenia receiving standardised, assured treatment and to identify predictors and moderators of the effects.Methods:We investigated the changes in body mass, fasting blood glucose and lipids in 107 largely antipsychotic naïve, first-episode schizophrenia patients who were treated according to a standard algorithm with long-acting injectable flupenthixol decanoate over 12 months.Results:Eighty-three (78%) participants completed the 12 months of treatment, and 104 (97%) received 100% of the prescribed injections during their participation. There were significant increases in BMI (P < .0001), waist circumference (P = 0.0006) and triglycerides (P = 0.03) and decrease in HDL (P = 0.005), while systolic (P = 0.7) and diastolic blood pressure (P = 0.8), LDL (P = 0.1), cholesterol (P = 0.3), and glucose (P = 0.9) values did not change over time. The triglyceride: HDL ratio increased by 91%. Change in BMI was only correlated with change in triglycerides (P = .008). The only significant predictor of BMI increase was non-substance abuse (P = .002).Conclusions:The risks of weight gain and metabolic syndrome associated with antipsychotic treatment in first-episode schizophrenia are not restricted to second generation antipsychotics. This is a global problem, and developing communities may be particularly susceptible.


2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S114-S115
Author(s):  
Stéfan Du Plessis ◽  
Hilmar Luckhoff ◽  
Sanja Kilian ◽  
Laila Asmal ◽  
Frederika Scheffler ◽  
...  

Abstract Background In this study, we explored the relationship between hippocampal subfield volumes and change in body mass over 12 months of treatment in 90 first-episode schizophrenia spectrum disorder patients (66 males, 24 females; mean age= 24.7±6.8 years). Methods Body mass index was assessed in patients at baseline, and at months 3, 6, 9 and 12. Hippocampal subfields of interest were assessed using a segmentation algorithm included in the FreeSurfer 6.0 software program. Results Linear regression analysis showed a significant interactive effect between sex and anterior hippocampus size as a predictor of change in body mass over 12 months, adjusting for age, substance use, treatment duration, and posterior hippocampal volumes. In an exploratory sub-analysis, partial correlations revealed a significant association between weight gain and smaller CA1, CA3 and subiculum volumes in females, but not males, adjusting for age and substance use, with similar trends evident for the CA4 and presubiculum subfields. Discussion In conclusion, our findings suggest that smaller anterior hippocampal subfields are associated with the development of weight gain over the course of treatment in first-episode schizophrenia spectrum disorders in a sex-specific fashion, and may partly explain the more severe and ongoing increase in body mass evident for female patients.


2015 ◽  
Vol 7 (3) ◽  
pp. 339-340
Author(s):  
Na Li ◽  
Wei Deng ◽  
Qian He ◽  
Tao Li ◽  
Hong Deng

2014 ◽  
Vol 153 ◽  
pp. S312
Author(s):  
Robin Emsley ◽  
Laila Asmal ◽  
Bonginkosi Ciliza ◽  
Stefan du Plessis ◽  
Jonathan Carr ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document